# Improving Overactive Bladder Treatment Access and Adherence Through Personalized Behavioral Modifications and Mobile Technology-Based Interventions

> **NIH NIH K23** · STANFORD UNIVERSITY · 2024 · $193,776

## Abstract

PROJECT SUMMARY/ABSTRACT
Poor access and insufficient patient education regarding OAB chronicity, expected outcomes, costs, and
potential side effects lead to unrealistic patient perceptions about therapy and suboptimal therapy duration,
particularly in vulnerable populations. This thus leads to poor treatment access, adherence, and
undertreatment. My long-term goal is to develop as an independently funded investigator and international
leader who will pioneer interventions that improve OAB therapy access, adherence and outcomes, thereby
reducing the burden of this chronic condition. The overall objective for this K23 proposal is to design an
innovative, stakeholder-informed strategy that incorporates barriers to treatment (such as social determinants
of health) and improves patient access to therapy options and therapy adherence. The central hypothesis is
that unmet patient expectations and knowledge due to lack of access and suboptimal provider-to-patient OAB
healthcare delivery are a barrier to treatment adherence. This central hypothesis will be tested pursuing two
specific aims: 1. Evaluate an adapted UI mobile health tool for use in a diverse, multicultural population of
women with OAB and identify barriers and facilitators to access, treatment adherence and engagement from
multiple key stakeholders. 2. Conduct a pilot study to evaluate the usability and feasibility of using a mobile
health tool to improve OAB knowledge, engagement and treatment plan adherence in a diverse group of
women with OAB. The rationale for the proposed research is that its completion is expected to provide a strong
evidence-based framework for the continued development and future implementation of cost-effective,
evidence-based interventions to improve OAB therapy access and adherence. Combined these results are
expected to have an important positive impact by positioning me to submit a competitive R01 application
proposing a randomized controlled efficacy trial for improving therapy access, adherence, and OAB outcomes
during the fourth year of this award.

## Key facts

- **NIH application ID:** 10893433
- **Project number:** 5K23DK131315-03
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** Ekene Enemchukwu
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $193,776
- **Award type:** 5
- **Project period:** 2022-08-15 → 2027-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10893433

## Citation

> US National Institutes of Health, RePORTER application 10893433, Improving Overactive Bladder Treatment Access and Adherence Through Personalized Behavioral Modifications and Mobile Technology-Based Interventions (5K23DK131315-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10893433. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*